John C Schmitz
Overview
Explore the profile of John C Schmitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
640
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang G, Pannucci A, Ivanov A, Switchenko J, Sun S, Sica G, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941812
To investigate the preclinical efficacy and identify predictive biomarkers of polo-like kinase 1 (PLK1) inhibitors in small cell lung cancer (SCLC) models. We tested the cytotoxicity of selective PLK1 inhibitors...
2.
Krishnamurthy A, Wang H, Rhee J, Davar D, Moy R, Ratner L, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):27.
PMID: 39841295
Background: ATR is an apical DDR kinase activated at damaged replication forks. Elimusertib is an oral ATR inhibitor and potentiates irinotecan in human colorectal cancer models. Methods: To establish dose...
3.
Beard J, Love S, Schmitz J, Hoskins A, Koide K
ACS Med Chem Lett
. 2024 Dec;
15(12):2225-2230.
PMID: 39691513
Meayamycins are synthetic analogs of the natural product FR901464 and exhibit potent anticancer activity against human cancers. They bind SF3B1 and PHF5A, components of the human spliceosome, and they alter...
4.
Pohorilets I, Beard J, Driscoll J, Schmitz J, Koide K
Bioorg Med Chem Lett
. 2024 Apr;
104:129739.
PMID: 38599298
FR901464 is a natural product that exhibits antiproliferative activity at single-digit nanomolar concentrations in cancer cells. Its tetrahydropyran-spiroepoxide covalently binds the spliceosome. Through our medicinal chemistry campaign, we serendipitously discovered...
5.
Beard J, Bressin R, Markaj P, Schmitz J, Koide K
J Med Chem
. 2023 Oct;
66(21):14497-14512.
PMID: 37870431
FR901464 is a cytotoxic natural product that binds splicing factor 3B subunit 1 (SF3B1) and PHD finger protein 5A (PHF5A), the components of the human spliceosome. The amide-containing tetrahydropyran ring...
6.
Liu H, Liu H, Zhou Z, Chung J, Zhang G, Chang J, et al.
Cell Commun Signal
. 2023 Jun;
21(1):147.
PMID: 37337282
Fluoropyridine-based chemotherapy remains the most widely used treatment for colorectal cancer (CRC). In this study, we investigated the mechanism by which the natural product Scutellaria baicalensis (Huang Qin; HQ) and...
7.
Wei N, Burnett J, Crocker D, Huang Y, Li S, Wipf P, et al.
Biochem Pharmacol
. 2023 Apr;
212:115564.
PMID: 37116665
Cellular protein synthesis is accelerated in human colorectal cancer (CRC), and high expression of protein synthesis regulators in CRC patients is associated with poor prognosis. Thus, inhibition of protein synthesis...
8.
Maguire W, Schmitz J, Scemama J, Czambel K, Lin Y, Green A, et al.
Cancer Chemother Pharmacol
. 2021 Jun;
88(4):643-654.
PMID: 34164713
Purpose: We investigated the combination of tivantinib, a c-MET tyrosine kinase inhibitor (TKI), and bevacizumab, an anti-VEGF-A antibody. Methods: Patients with advanced solid tumors received bevacizumab (10 mg/kg intravenously every...
9.
Tian N, Wu H, Zhang H, Yang D, Lv L, Yang Z, et al.
Bioorg Med Chem
. 2020 Jul;
28(16):115584.
PMID: 32690258
Triple-negative breast cancer (TNBC), a subset of breast cancers, have poorer survival than other breast cancer types. Recent studies have demonstrated that the abnormal Hedgehog (Hh) pathway is activated in...
10.
Bakkenist C, Czambel R, Lin Y, Yates N, Zeng X, Shogan J, et al.
DNA Repair (Amst)
. 2019 Jun;
80:1-7.
PMID: 31176958
Since many anticancer therapies target DNA and DNA damage response pathways, biomarkers of DNA damage endpoints may prove valuable in basic and clinical cancer research. Ataxia telangiectasia-mutated (ATM) kinase is...